Genetic causes of intellectual disability (ID) include mutations in proteins with various functions. However, many of these proteins are enriched in synapses and recent investigations point out their crucial role in the subtle regulation of synaptic activity and dendritic spine morphogenesis. Moreover, in addition to genetic data, functional and animal model studies are providing compelling evidence that supports the emerging unifying synapse-based theory for cognitive deficit. In this review, we highlight ID-related gene products involved in synaptic morphogenesis and function, with a particular focus on the emergent signaling pathways involved in synaptic plasticity whose disruption results in cognitive deficit. Intellectual disability (ID, also called learning disability, mental retardation or cognitive deficit) is defined by an overall intelligence quotient (IQ) lower than 70, associated with deficit in conceptual, social and practical adaptive skills with an onset before the age of 18 years.
Intellectual disability (ID, also called learning disability, mental retardation or cognitive deficit) is defined by an overall intelligence quotient (IQ) lower than 70, associated with deficit in conceptual, social and practical adaptive skills with an onset before the age of 18 years. 1 The clinical spectrum of cognitive deficit varies widely from non-syndromic ID to Autism spectrum disorder (ASD), and is estimated to affect 1-3% of the population. The causes of ID are heterogeneous and include genetic and/or environmental factors that influence the development and function of the central nervous system during the pre-, peri-or post-natal period. Genetic causes, including chromosomal abnormalities and monogenic causes, seem to be responsible for 40-50% of moderate to severe ID (IQ < 50), whereas environmental factors primarily contribute to mild ID (50 < IQ < 70).
In theory, genes that are involved in ID with a preserved central nervous system organization (that is, normal MRI scan) are likely to encode proteins that are necessary for the development of cognitive functions. Though at first sight, it may appear that these proteins are very diverse, a close analysis indicates that functional commonalities between these proteins are emerging (for example, transcription and chromatin remodeling factors, cell adhesion molecules, processing, modification and transport of RNA, protein ubiquitination and fatty acid metabolism function). Compelling evidence indicates that the major functional group of ID-related proteins corresponds to proteins that are enriched at synaptic compartments, and recent investigations point out the crucial role of these synaptic proteins in the subtle regulation of synaptic activity and morphogenesis of dendritic spines. [2] [3] [4] Since the 1970s, it has been shown that ID is associated with abnormalities in dendritic spine morphology and density. 5, 6 Spines are highly dynamic structures with diverse morphologies that range from filopodia, an immature form, to 'mushroom-shaped' protrusion which are spines characterized by a globular head connected to the dendritic shaft by a thin neck. 7 Dynamic changes in spine morphology result from membrane and actin cytoskeleton remodeling, and are highly regulated by numerous molecules during synaptogenesis and neuronal network activity. Synaptic plasticity such as longterm potentiation (LTP) or long-term depression, which require changes in actin cytoskeleton, induces structural plasticity of dendritic spines, that in turn contributes to changes in synaptic efficacy in a different time window. 8 Therefore, as previously suggested by Fiala et al., 7 the dilemma still remains as to whether the observed changes in dendritic spine morphology/density in ID patients are due to loss of intrinsic molecules or due to a compensatory response to reduce neuronal activity.
As genetic basis and genes involved in ID are regularly reviewed, here we present a focused review on the molecular and functional data supporting the emerging synapse-based theory for cognitive deficits, 'synaptopathy', with an emphasis on three major synaptic signaling pathways involving various small GTPases and also JNK. Recent remarkable progress, which allows to establish consistent correlations between deregulation of well-known signaling pathways and synaptic dysfunction, should open interesting therapeutic perspectives, as drug-based therapeutic approaches could be used to target these pathways and rescue their disrupted functions.
The RhoGTPase pathway
Among the small-G protein family, RhoGTPases (that is, RhoA, Rac and Cdc42) are known to be key regulators of actin cytoskeleton dynamic, and are involved in membrane trafficking such as exo-or endocytosis. 9 RhoGTPases work like molecular switches that oscillate between an active form bended to GTP and an inactive one bended to GDP. 9 The change from one state to another is tightly regulated by several proteins: GEF (GDP/GTP exchange factor) proteins facilitate their activation, GAP (GTPaseactivating protein) proteins facilitate their inactivation and GDI (GDP dissociation inhibitor) proteins stabilize the inactive form out from the membrane. 9 Regulators as well as effectors of RhoGTPases are involved in ID. 6 The first gene of the RhoGTPase pathway that was reported to be involved in ID encodes the RhoGAP protein, oligophrenin1 (Ophn1). Currently, all OPHN1 mutations cause protein loss-of-function (lof) [10] [11] [12] [13] [14] (Figure 1 ). Interestingly, OPHN1 duplication has also been associated with ID suggesting that OPHN1 dosage is important for cognition. 15 One main function of the RhoGTPases is to regulate actin cytoskeleton organization. Consequently, they are key modulators of neuronal morphology including dendritic spines, which are commonly affected in ID diseases. 16 The consensual view is that the Rac and Cdc42 pathways promote whereas the RhoA pathway inhibits the growth and/or stabilization of dendritic spines. 6, 17 To test the involvement of Ophn1 in neuronal morphology, various models of Ophn1 inactivation were developed in rodents. The Ophn1 knock-out (KO) model presents some similarities with human pathology including ventricular dilatation and, at the behavioral level, shows hyperactivity and spatial learning deficits. 18 Ophn1 gene inactivation does not affect the global neuronal development in the mouse brain. 18 In situ analyses of CA1 hippocampal Ophn1 KO mouse neurons 18 as well as in vitro studies where Ophn1 expression is knockeddown in rat hippocampal slices show a reduction of both the length and density of dendritic spines. 19, 20 Interestingly, treating slices with Y-27632, an inhibitor of Rho kinase (ROCK), a RhoA downstream effector, rescues the phenotype. 19 Through inhibition of the RhoA/ROCK pathway, Ophn1 is proposed to maintain the size of dendritic spines. In this model, reduction of Ophn1 level relieves the repression on RhoA, and consequently ROCK activity increases, which lead to a reduction of spine size presumably by acting on the actin-myosin contractile system (Figure 2e) .
In addition to its function in dendritic spine morphogenesis, we and others have shown that Ophn1 is involved in Clathrin-mediated endocytosis. 21, 22 Ophn1 interacts directly through its prolinerich regions with the SH3 (Src homology region 3 domain)-containing adaptor molecules: Amphiphysin I and II, CIN85 and endophilin. 21 These are key actors of Clathrin-mediated endocytosis and are involved in the formation of endocytic vesicles. 23 These interactions allow the recruitment of Ophn1 to endocytic sites, where Ophn1 can interact with curved membrane through its BAR (Bin/Amphiphysin/Rsv) /PH (Pleckstrin homology) domains and control the RhoGTPases to induce a local remodeling of subcortical actin cytoskeleton 21 ( Figure 2e ). Because of hyperactivation of RhoA/ROCK pathway, endocytosis and vesicle recycling are altered in both pre-and postsynaptic compartments of Ophn1 KO neurons ( Figure  2e) . 21 At the pre-synaptic site, Ophn1 lof impairs synaptic vesicle (SV) endocytosis, SV recycling and SV pools replenishment. 21, 22 In Ophn1 KO mice, the number of SV available for release is reduced in hippocampus (John Jefferys, personal communication) and an increase of the short-term synaptic depression is observed at Schaffer collateral (SC)/ CA1 synapses. 22 At the post-synaptic site of Ophn1 KO neurons, internalization of AMPA-R (a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor) subunit GluR1 is reduced 21 Consequently, NMDA (N-methyl-D-aspartate)-dependent long-term depression is affected at SC/CA1 synapses of Ophn1 KO animals. 21 In addition, Van Aelst's group shows that Ophn1 interacts with GluR1 and GluR2 subunits of AMPA-R and stabilizes them at the synapses. This Ophn1 function is dependent on synaptic activity through NMDA-R activation 20, 22 In the light of these recent data, Ophn1, through the regulation of actin cytoskeleton dynamic and Clathrin-mediated endocytosis, is involved in the coordination of structural and functional changes that occur during synaptic plasticity, a function shared with others ID/ASDrelated proteins (Figure 2 ).
Other regulators of RhoGTPases are involved in ID (Figure 1 ). The srGAP3/MEGAP (slit-robo GAP3/ Mental disorder associated GAP) gene, which encodes the WAVE1-associated Rac GAP, has been identified through the characterization of a balanced translocation in a patient with severe ID (Figure 1 , t(X;3)) and is deleted in 3p-syndrome. 24 However, the involvement of srGAP3 in ID is still a matter of debate due to the recent report of a heterozygous srGAP3-truncating mutation found in three healthy individuals and one patient from a single family 25 ( Figure 1, Q388X) . In vitro, srGAP3 regulates Rac and Cdc42 activities 24 ( Figure 2e ) and is involved in the induction of filopodia. 26 However, this function seems to depend only on the activity of the Inverse F-BAR domain and should be partially preserved in the family with Q388X mutations (Figure 1 ). Finally, both heterozygous and homozygous mouse models targeting this domain present memory deficits, thereby reinforcing the hypothesis that haploinsufficiency of srGAP3 (and more precisely the Inverse F-BAR domain) is pathogenic. 26, 27 ID-associated GEFs for Cdc42 include the Faciogenital dysplasia protein, whose mutations lead to 
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Small GTPases either the Aarkog-Scott syndrome 28, 29 or non-syndromic ID 30 and ARHGEF9/Collybistin (Cb), whose mutations are associated with ID and epilepsy. 31, 32 Genetic invalidation of Cb in mice shows a regionspecific reduction of gephyrin, a post-synaptic scaffolding protein, with a concomitant loss of specific GABA A receptors at inhibitory synapses. 33 These lead to an increase of network excitability in Cb KO hippocampus and changes in synaptic plasticity, which may explain the learning deficit observed in the spatial version of the Barnes maze. 33, 34 At the molecular level, the formation of gephyrin scaffolds at inhibitory synapses is independent of Cdc42, which questions the GEF function of Cb, but requires the attachment of Cb to post-synaptic membranes through its PH domain and PIP3 interactions. 35 Interestingly, Neuroligin 2 (NLGN2), the post-synaptic adhesion molecules of inhibitory synapses, binds gephyrin and activates Cb to allow the translocation of the complexes to the plasma membrane at perisomatic synapses. 36 This post-synaptic scaffolding assembly allows the clustering of inhibitory neurotransmitter receptors. From these studies, Cb deficiency in humans would result in the imbalance between excitatory and inhibitory neurotransmissions that lead to seizure susceptibility and ID.
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Two mutations in the ARHGEF6 gene encoding a-PIX (a-p21-interacting exchange factor), a GEF specific to Rac and Cdc42, have been found in patients with ID 37 ( Figures 1 and 2e) . However, the genetic evidence of its involvement (one translocation breakpoint and one putative splice mutant) is not clear. aPIX knockdown in neurons leads to immature synapses but in vivo confirmation is still awaited. Although the KO mouse model has been characterized in the immune system context, there are no studies regarding the brain function in mutants. 38 In addition to regulators of RhoGTPases, their effectors are also involved in ID. In the PAK3 (p21 protein (Cdc42/Rac)-activated kinase 3) gene, which encodes for a direct downstream kinase of Rac and Cdc42, one stop mutation and three missense mutations have been described in male patients with ID [39] [40] [41] [42] ( Figure 1 ). The LIMK1 (Lin-11, Isl-1 and Mec-3 kinase) gene is deleted in the continuous gene syndrome of Williams-Beuren, which includes among others features a mild ID. 43 All the three proteins aPIX, PAK3 and LIMK1, which is a direct downstream kinase of PAK3, are involved in the regulation of actin cytoskeleton dynamic and share a common effector, cofilin, an effector of LIMK1 that is directly involved in actin filament depolymerisation 44 ( Figure 2e) .
Various overexpression and knockdown approaches in neuronal cell culture and in transgenic animals have confirmed the involvement of aPIX, PAK3 and LIMK1 in dendritic spine morphology. [45] [46] [47] [48] In hippocampal neurons, PAK3 knockdown leads to an immature phenotype with abnormally elongated dendritic spines and filopodia-like protrusions along with a decrease in mature spine synapses. 46 Functional characterization of PAK3 human mutations ( Figure 1 ) on dendritic spines morphology/density revealed differential effects depending whether the mutations disrupt the kinase activity ( Figure 1 , A365E and R419X) or the binding of the PAK3 (Figure 1 , R67C) to its GTPase Cdc42. 47 It also showed PAK3 involvement in both initiation and maturation of spines.
47 Surprisingly, analyses of PAK3 KO mice show no morphological spine defect suggesting in vivo redundancy among the different PAK members during development, which would compensate for the actin cytoskeleton dynamic deficit. 49 Associative learning in PAK3 KO model is impaired along with long-term synaptic plasticity which is likely due to alteration of CREB (cAMP response element binding protein)-signaling pathway. 49 Thus, in addition to controlling actin cytoskeleton dynamic (Figure 2e) , the Rac-Cdc42/PAK3 signaling pathway would also have long-term effects on the synapses by modulating neuronal gene expression in response to neuronal activity. Interestingly, aPIX knock down phenotype in neurons is rescued by expression of a constitutively active mutant of PAK3 suggesting the implication of these proteins in a common pathway 50 ( Figure 2e ).
Ras signaling (SAP102/SynGAP/Ras/ERK)
Among the large family of small G proteins, the upstream regulators of RasGTPases have been involved in ID and/or ASD. Indeed, the autosomal SYNGAP1 gene encoding for the RasGAP SynGAP (Synaptic GTPase activating protein) has recently been found to be involved in ID. 51 Three de novo point mutations have been identified at the heterozygous status in patients with mild to severe nonsyndromic ID 51 ( Figure 1 ). It is constituted of a central RasGAP domain that is flanked on the amino-terminal side by a PH domain and a C2 domain (a calciumdependant phospholipid-binding domain), and on the carboxy-terminal side by a SH3 domain and a CC (Coiled-Coil) domain (Figure 1 ). Alternative splicing of pre-mRNA produces several isoforms. Some isoforms have a PDZ (PSD-95/Disc large/Zonula occludens)-binding domain which mediates interactions with the post-synaptic scaffolding proteins PSD-95 (Post-synaptic density-95) and SAP102 (Synapse associated protein 102), 52 whereas other isoforms have a CaMKII (Calmodulin kinase II)-binding domain, 51 The SAP102 protein, encoded by the X-linked DLG3/SAP102 gene, is also involved in cognitive deficit. 53 As the other MAGUKs (Membrane-associated guanylate kinase), SAP102 is constituted of three PDZ domains, one SH3 domain and a GK (Guanylate kinase) domain with no kinase activity ( Figure 1 ) but with binding capacities to both actin and microtubule cytoskeletons. The SAP102 PDZ domains have a strong affinity for the type I PDZbinding domains of various synaptic proteins including transmembrane proteins as Neuroligin and NMDA-receptor subunits and signaling molecules such as SynGAP and neuronal NO Synthase. 54 Five different mutations in the SAP102 gene have been found in patients with mild to severe ID 53, 55 ( Figure 1 ). For now, mutations in either SAP102 or SYNGAP1 gene are mainly non-sense or frameshift mutations that lead to a truncated protein or to degradation of the transcript through nonsense-mediated mRNA decay mechanism. Similar to human lof, null-mutation in the mouse SAP102 gene is not lethal but results in deficits in the initial phase of spatial learning along with an enhancement of hippocampal synaptic plasticity. 56 Three different SynGAP KO mouse models have been developed. [57] [58] [59] Homozygous mutants are lethal postnatally, whereas heterozygous animals, similarly to the human haploinsufficiency of SYNGAP1 gene, present deficits in learning and in hippocampal LTP. [57] [58] [59] From studies on SynGAP and SAP102 KO mouse models emerge a common altered mechanism that involves the Ras/ERK pathway in the coupling of NMDA-R activation, that is, neuronal activity, with AMPA-R trafficking (Figure 2d ). Ras/MEK/ERK pathway and Ras/PI3K/PKB (PI3K: Phosphoinositid-3 Kinase, PKB: PI3K kinase B) pathway, respectively, phosphorylate GluR2L and GluR1 AMPA-R subunits that consequently stimulate AMPA-R insertion into the post-synaptic membrane (Figure 2d) . 60 Both SynGAP and SAP102 KO models present a hyperactivation of the ERK pathway (that is, increased levels of phosphorylation of MEK and its downstream ERK kinase). 56, 58 How SynGAP couples NMDA activation to AMPA-R trafficking is still a matter of debate. One model proposes that after NMDA stimulation, activated CaMKII directly phosphorylates SynGAP, which increases its GAP activity, thereby inhibiting the Ras pathway 61 ( Figure 2d) . Consequently, SynGAP haploinsufficiency would relieve the inhibition on both Ras/MEK/ERK and Ras/PI3K/PKB pathways, and would thus increase AMPA-R number at the postsynaptic membrane. 57, 59 This impairment of response to NMDA activation could explain the deficit in LTP induction observed in the hippocampus of SynGAP KO mice. 58 In the hippocampus of SAP102 KO mice, ERK-dependent LTP (theta-burst-induced LTP) is increased, and inhibition of ERK kinases is sufficient to rescue the phenotype. 56 These physiological results suggest different consequences of ERK pathway hyperactivation on AMPA-R trafficking in SAP102 and SynGAP KO models. The only partial crosscheck between SAP102 and SynGAP KO phenotypes could be explained by SynGAP's ability to interact with other AMPA R NMDA R
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Post-synaptic compartment MAGUKs, especially PSD-95. Indeed, SAP102 specifically interacts with NR2B (NMDA-R 2B) subunits, whereas PSD-95 interacts with NR2A subunits; these two complexes seem to have opposite effects on ERK pathway and downstream AMPA-R trafficking. 62, 63 Further characterization of AMPA-R trafficking in SAP102 KO model would be useful to more precisely determine the common features of the SynGAP and SAP102 KO models. In addition to the Ras pathway, Kennedy's group 59, 61 demonstrated that SynGAP lof also results in Rac hyperactivation that affects dendritic spine morphology (Figure 2d) . In KO neurons, NMDA application fails to induce dephosphorylation of cofilin, whereas in wild-type conditions, NMDA application via cofilin dephosphorylation stimulates actin filament destabilization. 61 SynGAP and cofilin are connected by Rac/PAK/LIMK pathway which can be indirectly stimulated by Ras through activation of Tiam1 or Kalirin7, two RacGEFs (Figure 2d) . Notably, even though SynGAP, Ophn1 and others belong to different signaling pathways, there is some cross talk between these pathways and there are some convergent outcomes. The ID linked to their mutations would result from alteration of two processes involved in synaptic plasticity: glutamate receptors trafficking and actin cytoskeleton dynamic (Figure 2) .
A downstream effector of the Ras/ERK pathway is also involved in a syndromic form of ID. Mutations in the RSK2 (90kDa ribosomal S6 Kinase) gene are associated with Coffin-Lowry syndrome 64 ( Figure 1 ). Activation of Rsk2 by ERK phosphorylation induces its partial translocation from the synapse to the nucleus where it regulates expression of gene through phosphorylation of histones 65 and several transcription factors, including CREB 66 (and for a review see ref 67 ). The consequences of Rsk2 lof on the expression of its target genes in neurons have been recently explored in the Rsk2-deficient mice, which show delayed acquisition of a spatial memory reference task and long-term spatial memory deficits. 68 In the hippocampus of Rsk2 KO mice, expression of GluR2 is increased, thus, modifying AMPAR properties and reducing basal AMPAR-mediated transmission. 69 Results from studies using neuroendocrine cells suggest that Rsk2 could also directly regulate synaptic processes such as exocytosis via direct phosphorylation of phospholipase D1, 70, 71 however, paired-pulse facilitation is not affected in Rsk2 KO mice showing that presynaptic function is unaltered. 69 Figure 2 Synaptic pathways involved in intellectual disability (ID) and possible therapeutic targets. Schematic view of the main synaptic pathways described in this review highlighting the commonly altered processes. In each inset, the molecular details of the pathway are described and the potential drugs for therapeutic (in light blue) and their targets are positioned in the signaling pathway. (a): Rab pathway; aGDI loss-of-function (lof) impairs synaptic vesicle (SV) trafficking through regulation of Rab4 and Rab5 activities whereas Rab39 function is still under investigation. (b) IL1RAPL1/JNK pathway; loss of IL1RAPL1 decreases JNK activity and consequently affects PSD-95 localization (light purple arrows) and possibly a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA-R) trafficking by decreasing GluR2L and GluR4 JNK-dependent phosphorylation (light purple dashed line). In the pre-synaptic compartment, SV exocytosis may be affected by IL1RAPL1 lof through disruption of IL1RAPL1/NCS-1 interaction and regulation of N-type voltage gated calcium channel activity (light purple dashed line). Finally, the involvement of IL1-b in the activation of IL1RAPL1/JNK pathway is represented in the synaptic cleft with a dashed green arrow. (c) ARF6 pathway: IQSEC2 interacts with synaptic scaffolding proteins, including PSD-95, and regulates ARF6 activity. However, the functional consequences of IQSEC2 lof on the physiological processes regulated by ARF6, which include membrane trafficking and actin cytoskeleton dynamic, are currently unknown (dashed brown line). TBC1D24 is a negative regulator of ARF6 but similarly to IQSEC2, very little is known about TBC1D24 lof consequence. (d) ERK pathway: N-methyl-D-aspartate (NMDA)-receptor activation after glutamate release leads to CaMKII activation that in turn phosphorylates SynGAP, thus increasing its GTPase-activating protein (GAP) activity. SAP102 and PSD-95 interact with both NMDA-R and SynGAP, and are likely to concentrate these molecules in the NMDA-R complex where they can easily interact. SynGAP activation inhibits both Ras/PI3K/PKB (not represented for the sake of clarity) and Ras/MEK/ERK pathways (orange line) resulting in the decrease of GluR2L and GluR1 phosphorylation and subsequent AMPA-R insertion. Ras inhibition indirectly inhibits the Rac pathway (dashed orange line), and as a result, regulates actin cytoskeleton dynamic. Both SAP102 and SynGAP lof disrupt the coupling between NMDA-R activation (that is, neuronal activity) and AMPA-R trafficking through a hyperactivation of the Ras/ERK pathway. In addition, SynGAP lof disrupts the coupling between NMDA-R activation and actin cytoskeleton dynamic through a hyperactivation of the Rac pathway whereas no such effect has yet been described for SAP102 lof. (e) RhoGTPase pathway; The RhoGAP Ophn1 inhibits the RhoA/ROCK pathway, which regulates the actin-myosin contractile system (purple line) and actin cytoskeleton dynamic through LIMK-1 phosphorylation (purple line). Ophn1 lof would release the inhibitory control on RhoA/Rock pathway leading to destabilization of the actin cytoskeleton. LIMK-1, a common effector for the RhoGTPases including Rac and Cdc42, phosphorylates cofilin, thereby limiting actin filaments destabilization. Regulators aPIX and srGAP3 and effectors PAK3 and LIMK-1 of the Rac and Cdc42 pathways are involved in ID. Lof of PAK3, LIMK-1 and aPIX affect actin cytoskeleton dynamic. Possible therapeutic targets: in light blue. For SynGAP (inset d), SAP102 (inset d) and Ophn1 (inset e) linked-ID, inhibitors of farnesyl-transferase (BMS191563) or HMG-CoA reductase (Lovastatin) could be used to reduce the amount of activated small G proteins (RhoA or Ras). Hyperactivated kinases downstream of the SAP102/SynGAP pathway can be inhibited by RO4927350, PD0325901 or AZD6244 and kinases downstream of the Ophn1 pathway can be inhibited by Y-27632 or HA1077. Finally, epilepsy, associated with ID, can be treated with valproate or topiramate to reduce the number of active AMPA-R by decreasing GluR1 subunit activity or number, respectively. Molecules marked with an asterisk are already used to treat these pathologies.
Rsk2 is downstream of the Ras/ERK pathway, and SynGAP or SAP102 lof induces hyperactivation of Ras/ERK pathway. This raises the question as to whether Rsk2 is hyperactivated in SynGAP or SAP102 KO models. For now, no modification of the level of expression of Rsk2 target genes in SynGAP or SAP102 KO models has been described. As ERK is involved in the regulation of many cellular processes, it is likely that the hyperactivation of ERK pathway in both SynGAP and SAP102 KO models is restricted to the synaptic compartment. Whether this restriction is due to spatial compartmentalization or to specificity of SynGAP or SAP102 control on ERK activity remains an open question.
Other small GTPases: the Rab and Arf pathways
Finally, other families of GTPases are involved in ID with mutations in genes coding for Rab aGDI regulator, 72 Rab39 GTPase 73 and the putative RabGAP TBC1D24 74, 75 ( Figure 1 ). ID is either isolated (GDI1) or associated to epilepsy (Rab39 and TBC1D24). Functional characterization of aGDI KO mice shows a complex phenotype due to the multiple Rab GTPases regulated by aGDI (Rab 4 and 5) but the alterations of short-term plasticity along with alterations of the SV reserve pool point toward a presynaptic function of aGDI in SV trafficking via the endosomes 76 ( Figure  2a ). Regarding Rab39, whose function is under investigation, its knockdown in hippocampal neurons alters the growth cone morphology and neurite arborization, and results in a strong reduction of synapses. 73 In contrast to the role of aGDI in SV trafficking, Rab39b mutations seem to disrupt neuronal development rather than function, making Rab39 an unlikely direct target of aGDI.
Three missense mutations in the two main domains of TBC1D24 (Figure 1 ) have been reported in two large consanguineous families and result in partial or complete lof. 74, 75 Indeed, overexpression of wild-type protein in hippocampal or cortical neurons affects neuronal morphology increasing the length and branching of neurites whereas the mutants suppress this 'gain of function' phenotype. The first domain (Figure 1 ; TBC) is characteristic of RabGAP proteins; however, it lacks the classical arginine finger, which is necessary for GAP activity. Therefore, TBC1D24 is probably not a negative regulator of Rab GTPases but, similar to other members of this arginine-deficient family, it binds to the small GTPase ADP ribosylation factor 6 (ARF6) via its TBC domain and negatively regulates its activity 75 ( Figure 2c ). ARF6 is an activator of PIP5K (phosphatidylinositol 4-phosphate 5-kinase) that generates a multifunctional lipid messenger, PI(4,5)P 2 , and it has a primary role in the regulation of membrane trafficking and actin cytoskeleton reorganization contributing to various cellular functions including exocytosis, endocytosis and endocytic recycling. [77] [78] [79] ARF6 regulates neuronal differentiation and controls axonal and dendritic formation, including dendritic spines. 80 Through its participation in endocytosis, ARF6 also controls synaptic plasticity together with the ARF GEF protein BRAG2, especially during long-term depression, when AMPAR are internalized and recycled. 81 It would be interesting to test in similar 'gain of ARF6 function' experiments whether TBC1D24 mutations also affect synaptic plasticity in addition to neurite growth. 74, 75 Another ARF6 GEF, IQSEC2 (Brag1 or IQ-ArfGEF), which interacts with two scaffolding proteins of the excitatory synapse, IRSp53 82 and PSD-95, 83 has been found mutated in four non-syndromic X-linked ID families 84 ( Figure 1 ). The four missense mutations are located in the sec7 and IQ-like domains and reduce GEF activity towards ARF6 85 suggesting that reduced ARF6 activity is pathogenic (Figure 2c ) and associated with ID whereas overactivation in ARF6 is responsible for epilepsy in patients with TBC1D24 mutations. 74, 75 JNK signaling: IL1RAPL1/JNK/PSD-95
Similarly to IQSEC2 binding to PSD95, the recently described interaction between PSD95 and IL1RAPL1 (Interleukin-1 receptor accessory protein like 1) sheds light on the JNK pathway and its involvement in ID and ASD.
IL1RAPL1 is a transmembrane protein and belongs to a novel family of IL1/Toll receptor with homology to IL-1 Receptor accessory protein (IL-1RacP). Apart from the classical organization of IL1-R family members (Figure 1 ), IL1RAPL1 has an additional 150 amino acids at the carboxy-terminal end similarly to that of its paralog IL1RAPL2 86 ( Figure 1 ). IL1RAPL1 interacts through its carboxy-terminal domain with NCS-1, a neuronal calcium sensor 87 and through its non-classical type I PDZ-binding domain with PSD-95.
88 IL1RAPL1 mutations are associated with X-linked non-syndromic form of ID 86 and with autism with ID. 89 Various mutations have been described 86, [89] [90] [91] ( Figure 1 ) and they may produce truncated proteins, but the mutated mRNAs are likely to be degraded similarly to the first-described point mutation. 86 In neuroendocrine PC12 cells, overexpression of IL1RAPL1 recruits NCS-1 at the membrane, which inhibits N-type voltage gated calcium channel activity 92 and consequently, secretory granule exocytosis. 87 As IL1RAPL1 and NCS-1 are both present in the presynaptic compartment of neurons, IL1RAPL1 could regulate voltage gated calcium channel activities at the synapses and consequently SV exocytosis in neurons (Figure 2b ). Nevertheless, there is no evidence of such IL1RAPL1 function in vivo.
Finally, one missense mutation in the binding domain of NCS-1 has been found in an ASD patient, but it does not disrupt the interaction with IL1-RAPL1 89, 93 ( Figure 1 ). The mutation seems to affect the Ca 2 þ -dependent dynamic of NCS-1 at the plasma membrane but the physiological consequences on voltage gated calcium channel are still unknown.
In addition to NCS-1, IL1RAPL1 also interacts with PSD-95, a major scaffolding protein of excitatory synapses. 88 In mice, IL1RAPL1 lof leads to a decrease of dendritic spine number in the CA1 region of the hippocampus and reduces theta-burst-induced LTP at SC-CA1 synapses. 88 Intriguingly, in Il1rapl1 KO neurons, JNK activity is decreased and subsequently, the level of phosphorylation of its target PSD-95 94 leading to a reduction of PSD-95 localization at the synapse 88 ( Figure 2b) . Therefore, IL1RAPL1 interacts with and controls PSD95 localization by modulating JNK activity. 88, 95, 96 In addition, IL1RAPL1 could also regulate AMPA-R trafficking through modulation of either PSD95 or GluR2L/GluR4 phosphorylation 97 levels by JNK (Figure 2b) .
Previously, we have seen that some ID-related proteins act as coordinators of synaptic plasticityrelated changes and neuronal activity. In contrast, the deficit in JNK activity due to IL1RAPL1 lof seems to be independent of neuronal network activity. 88 Interestingly, IL-1b treatment of IL1RAPL1 KO neurons fails to activate JNK phosphorylation whereas activation of other MAPKs still occurs. 98 Thus, IL1RAPL1 is required specifically for IL-1b-mediated activation of JNK in neurons suggesting a role similar to its close homolog IL1RacP (Figure 2b) . Classically, IL-1b binds to its receptor IL1R, and this binding induces IL1R-IL1RacP heterodimerization through their Ig-like domains. 99 This heterodimerization allows interaction between their TIR domains which results in activation of the downstream pathway. 99 Intriguingly, crystallographic studies reveal that IL1RAPL1 TIR domains are likely to form homodimers. 96, 99 The simplest hypothesis is that IL-1b binding to IL1-RAPL1 induces its homodimerization to activate JNK pathway, but for now there is no evidence of a direct binding of IL1-b to IL1RAPL1 (Figure 2b) . Apart from the role of IL1-b in immunity and inflammation, new functions have recently emerged in neuronal physiology. At low concentration, that is, physiological concentration, IL-1b is involved in hippocampal LTP maintenance 100 Moreover, both the IL-1R KO model and transgenic mice overexpressing the IL1-Receptor antagonist (IL-1Ra) in the central nervous system have deficits in theta-burst-induced LTP at SC/CA1 synapses as well as impairments in spatial memory, 101, 102 similar to the IL1RAPL1 KO model (unpublished data). Altogether, these data highlight the relevance of the IL-1/IL1RAPL1/JNK pathway in cognitive disorders with ID or ASD.
Others ID molecules connected to synapses
It is interesting to note that amongst the different ID proteins discussed in the review, a few of them (SynGAP, IQSEC2, IL1RAPL1, Cb) are directly linked to PSD95 or gephyrin, two major scaffolding proteins involved in the organization of excitatory and inhibitory synapses, respectively, and that mutations in these genes affect either the NMDA/AMPA ratio or the balance between excitation and inhibition.
Members of the Neuroligin family are also partners of PSD95 or gephyrin and mutations in some of them (that is, NLGN3 and NLGN4), are responsible for various cognitive disorders, including ASD and schizophrenia. 103 Studies of mouse models have shown that these cell-adhesion molecules are not required for initial synaptogenesis but for synaptic function. Neuroligin interactions with their transsynaptic partners, members of the Neurexin family would mediate bi-directional signaling in both preand post-synaptic compartments although the downstream molecular cascades are still unknown. Depending of their synaptic localization or the synaptic context (that is, brain regions) either excitatory and/or inhibitory transmissions are affected by mutations in the various mouse models; these variations may explain the clinical heterogeneity observed in patients with ASD even with the same mutation. 104, 105 From molecular mechanisms to therapeutic approaches Knowing the pathological mechanisms of ID, two different therapeutic strategies can be considered. One is based on the proteins that are involved in the affected signaling pathways whereas the other is based on the biological processes altered by the mutation.
Through different investigations aimed at dissecting the molecular pathways in which ID proteins are involved, the emerging picture is that many of them belong to well-known signaling pathways for which potential therapeutic molecules that modulate their activity could be tested in preclinical trials (Figure 2 , in light blue). For instance, most mutations affecting small GTPases lead to hyperactivation of the pathway. In order to lower the signal transduction, one can use either general inhibitors of small GTPase or more specific ones to target downstream kinases. In addition to the previously described regulators, the activity of small GTPases is positively regulated by posttranslational modifications such as isoprenylation and farnesylation, both of which increase the small GTPases stability at the membrane. Inhibition of farnesyl-transferase or HMG-CoA reductase with BMS191563 and molecules from the Statin family, respectively, have been successfully used to reduce Ras activation level in the mouse model of Neurofibromatosis type 1, a complex neurodevelopmental disorder due to lof of a RasGAP, NF1 106, 107 (for a review see ref. 108 ). Thus in the OPHN1, SAP102 or SYNGAP linked-ID in which there is a hyperactivation of small GTPases (Figure 2 ), such approaches should be considered and evaluated using the available animal models.
Alternatively, inhibition of downstream kinases of RhoGTPases pathway has already yielded promising results in the Ophn1 KO model: application of ROCK inhibitor Y27632 to cell cultures or hippocampal slices rescued some of the deficits observed in Ophn1 KO animals. 19, 21 Promisingly, evidence from various animal models with an hyperactivation of RhoA/ ROCK [109] [110] [111] and evidence from clinical use of ROCK inhibitors fasudil (HA-1077, Asahi Chemical Industry, Tokyo, Japan) in cardiovascular diseases 112 opens therapeutic perspectives for OPHN1-linked ID ( Figure  2e ). Thus, we can ask whether a similar strategy, that is, inhibition of Ras downstream kinases, could be used to rescue AMPA-R trafficking alterations present in the SAP102 and SynGAP KO models. As hyperactivation of the Ras/MEK/ERK pathway is also involved in other pathologies such as cancer, specific inhibitors of MEK like RO4927350 are developed for clinical purposes and some of them such as PD0325901 or AZD6244 are already under clinical trials 113, 114 (Figure 2d ). However, none of these molecules have been tested in the SynGAP or SAP102 models nor have their effects on neurons physiology been characterized.
Alternatively, mutations in other ID genes lower or inactivate some ubiquitous pathway like the aPIX/ Rac/PAK3/LIMK or IL1RAPL1/JNK pathways. In these cases, the strategies involve activation of the downstream effectors or relief of the inhibitory control on the pathway using GTPases or phosphatases. In the case of aPIX lof that leads to reduced activation of Rac and Cdc42, an interesting possibility comes from the Escherichia coli toxin CNF1 (cytotoxic necrotizing factor 1). In mice, intracerebroventricular injection of this toxin leads to hyperactivation of Rac through posttranslational modifications that last at least 28 days after the injection. 115 This hyperactivation of Rac is associated with improvements in both spatial learning and synaptic plasticity in the hippocampus. 115 However, the potential beneficial effects of this toxin in the context of aPIX lof have not been explored. Both LIMK1 and JNK are known to be hyperactivated in various cancers, and inhibitors of PP1 and/or PP2A phosphatases are known to promote tumorogenesis. Thus, even if the use of PP1/PP2A phosphatase inhibitor okadaic acid rescues JNK and PSD-95 phosphorylation deficits in Il1rapl1 KO neurons, 88 it is inconceivable to consider it as a potential therapeutic treatment. Nonetheless, development of selective activators of JNK or PP1/ PP2A phosphatase inhibitors that target JNK synaptic pathway could be a relevant therapeutic option (Figure 2b) .
Finally, another strategy that targets downstream processes of the deregulated pathways could be proposed. We have seen that AMPA-Receptor trafficking or expression is frequently impaired in mouse models of ID (Figure 2 ). Drugs that target these processes could be tested as therapeutic molecules. In this line, different groups have reported that treatment reducing the level of synaptic active AMPA-R can improve symptoms, such as epilepsy, which is frequently associated with OPHN1-or SYNGAP1-linked ID 10, 51 (Figures 2d and e) . However, two major limitations to potential therapeutic approaches exist, and will have to be solved in the next decades. The first hurdle is how to specifically target the central nervous system alteration, though this challenge is common to all therapeutic strategies that target ubiquitous pathways. The second main limitation is associated with the timeframe in which the deficits appear and the time windows in which a potential treatment could rescue these deficits.
Concluding remarks
In summary, we have seen that a limited number of synaptic signaling pathways are involved in the regulation of neuronal connectivity and synaptic function and/or plasticity are commonly altered in ID. Rather than resulting from a deficit in one specific synaptic function, these pathologies could be the consequence of an absence or a mis-coordination of pathways normally induced during development of cognitive functions. Interestingly, as some of the IDrelated proteins are mainly required in post-natal stages, and that the resulting functional synaptic abnormalities could be rescued by using molecules targeting the implicated deregulated pathways, it is reasonable to believe that some forms of ID could benefit, and be improved, by adapted pharmacological therapeutic approaches.
